Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in miceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared three clinically prescribed ketogenic infant formulas (KetoCal KD4:1, KD3:1, MCT2.5:1) and a standard infant formula control, testing how each shapes the gut microbiome and resistance to seizures in mice.
How was it studied?
Juvenile mice were fed each formula for about a week, then tested for resistance to 6-Hz psychomotor seizures, a benchmark model of refractory epilepsy. Fecal metagenomic sequencing tracked microbiome changes, and a model human infant microbial community was used to screen individual dietary variables, including 13 different fiber sources, for their effects.
What did they find?
Dietary fiber, not fat ratio or fat source, drove the largest metagenomic shifts. KD3:1, which lacks dietary fiber, failed to protect against seizures, but raising its fiber content from 5.3 percent to about 10.3 percent restored seizure resistance. Adding extra fiber to an already protective formula further increased seizure resistance. Seizure-protective fibers, such as a fructooligosaccharide/inulin/cellulose/gum arabic mix, FOS alone, and orange fiber, enriched microbial genes for queuosine and preQ0 biosynthesis and reduced genes for sucrose degradation.
Why it matters
The findings suggest fiber content, more than fat composition, determines whether a clinical ketogenic formula protects against seizures, pointing to microbiome-guided fiber selection as a potential lever for improving epilepsy treatment.